![](https://investorshub.advfn.com/uicon/430424.png?cb=1554906782)
Thursday, July 20, 2017 5:33:51 PM
First, I'd make certain the tumor was saved, and a small amount of it biopsied for tumor type.
I'd undergo leukapheresis.
Next, if the tumor type was methylated MGMT, I'd not skip chemoradiation, but would strongly consider a shorter course (because of age) -- if Doctors agreed.
However, if my tumor was not methylated MGMT, I'd skip chemotherapy completely -- if my doctors agreed.
If my tumor was not methylated and my absolute lymphocyte count was extremely low, I'd not only skip chemoradiation, I'd also consider truncating radiation dramatically -- if my doctors agreed.
If my tumor type was either EGFRIII positive and/or HLA-A2+; and after the above took place, I'd immediately start one and/or both therapies - aka: Rintega and/or ICT-107- if my doctors agreed.
Once DCVax-L manufactured, I'd concurrently, ASAP, add DCVax-L therapy systemic subdermal doses, concurrent with regionally injected small doses of antiPD1 -- if my doctors agreed. (I might additionally ask if the doctors could also combine a small amount of anti-PD1 in the same syringe as DCVax-L.) -- if my doctors agreed.
I would follow all medical recommendations to increase my lymphocyte count every step of the way -- if my doctors agreed.
I would additionally seriously contemplate adjuvant hyperthermia treatments to the extent I could safely tolerate it -- if my doctors agreed.
If the cancer returned I would continue with the same, remove new tumor for new biopsy and to make new batch of DCVax-L; go through the decision making steps above again, but additionally add CTLA-4 injected regionally, and PLX-3397. -- if my doctors agreed.
Respect Risk. Conduct Your Own Due Diligence. Manage your assets wisely. Diversify.
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM